Literature DB >> 17179396

High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience.

Jeffrey J Hom1, Fergus V Coakley, Jeffry P Simko, Ying Lu, Aliya Qayyum, Antonio C A Westphalen, Lars D Schmitt, Peter R Carroll, John Kurhanewicz.   

Abstract

PURPOSE: To retrospectively determine the magnetic resonance (MR) and MR spectroscopic imaging features of high-grade prostatic intraepithelial neoplasia (HGPIN) in patients with prostate cancer.
MATERIALS AND METHODS: Approval of the committee on human research was obtained, with a waiver of consent for this HIPAA-compliant study. Endorectal MR imaging and MR spectroscopic imaging were performed in 48 men (mean age, 59 years; range, 47-75 years) prior to radical prostatectomy for prostate cancer. T2-weighted signal intensity and metabolic ratios of peripheral zone HGPIN foci of 6 mm or greater in diameter were recorded by two readers with knowledge of step-section histopathologic findings using areas of confirmed normal and cancerous peripheral zone tissue for comparison. A random effects statistical model was used to compare metabolic ratios from normal, HGPIN, and cancer voxels.
RESULTS: A total of 123 peripheral zone HGPIN foci with a mean diameter of 3 mm (range, 1-28 mm) were identified in 37 (77%) patients, but only 20 foci in 14 patients had a diameter of 6 mm or greater. Six foci were excluded, yielding 14 large HGPIN lesions from 11 patients in the final statistical analysis. The larger HGPIN foci were not associated with any focal reduction in T2-weighted signal intensity but demonstrated metabolic findings intermediate between normal and cancerous tissue; the mean ratios of choline (Cho) to creatine (Cr) for normal, HGPIN, and cancer were 0.92, 1.75, and 1.99, respectively, (P < .01), and the corresponding ratios of Cho plus Cr to citrate were 0.34, 0.50, and 0.78 (P < .01).
CONCLUSION: HGPIN is metabolically intermediate between normal peripheral zone tissue and prostate cancer at MR spectroscopic imaging but does not manifest any MR imaging abnormality and is rarely of sufficient size to cause substantial error in evaluation of peripheral zone tumor extent in patients with prostate cancer. (c) RSNA, 2007.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17179396     DOI: 10.1148/radiol.2422051828

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

1.  A magnetic resonance spectroscopy driven initialization scheme for active shape model based prostate segmentation.

Authors:  Robert Toth; Pallavi Tiwari; Mark Rosen; Galen Reed; John Kurhanewicz; Arjun Kalyanpur; Sona Pungavkar; Anant Madabhushi
Journal:  Med Image Anal       Date:  2010-10-28       Impact factor: 8.545

2.  Evidence that Human Prostate Cancer is a ZIP1-Deficient Malignancy that could be Effectively Treated with a Zinc Ionophore (Clioquinol) Approach.

Authors:  Leslie C Costello; Renty B Franklin; Jing Zou; Michael J Naslund
Journal:  Chemotherapy (Los Angel)       Date:  2015-06

Review 3.  A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Arch Biochem Biophys       Date:  2016-04-27       Impact factor: 4.013

4.  Metabolomics: a novel approach to early and noninvasive prostate cancer detection.

Authors:  Matthew J Roberts; Horst J Schirra; Martin F Lavin; Robert A Gardiner
Journal:  Korean J Urol       Date:  2011-02-19

Review 5.  A decade in prostate cancer: from NMR to metabolomics.

Authors:  Elita M DeFeo; Chin-Lee Wu; W Scott McDougal; Leo L Cheng
Journal:  Nat Rev Urol       Date:  2011-05-17       Impact factor: 14.432

6.  Endorectal MRI and MR spectroscopic imaging of prostate cancer: developing selection criteria for MR-guided focal therapy.

Authors:  Stephanie T Chang; Antonio C Westphalen; Priyanka Jha; Adam J Jung; Peter R Carroll; John Kurhanewicz; Fergus V Coakley
Journal:  J Magn Reson Imaging       Date:  2013-05-16       Impact factor: 4.813

Review 7.  Multiparametric magnetic resonance imaging in prostate cancer: present and future.

Authors:  John Kurhanewicz; Daniel Vigneron; Peter Carroll; Fergus Coakley
Journal:  Curr Opin Urol       Date:  2008-01       Impact factor: 2.309

Review 8.  [Prostate carcinoma].

Authors:  H-P Schlemmer
Journal:  Radiologe       Date:  2008-01       Impact factor: 0.635

9.  Multiparametric magnetic resonance imaging characteristics of normal, benign and malignant conditions in the prostate.

Authors:  Pieter J L De Visschere; Anne Vral; Gianpaolo Perletti; Eva Pattyn; Marleen Praet; Vittorio Magri; Geert M Villeirs
Journal:  Eur Radiol       Date:  2016-08-04       Impact factor: 5.315

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.